Zdenka Šklubalová

Zdenka Šklubalová

Auto-generated profile, based on publicly available information

Zdenka Šklubalová

Department of Pharmaceutical Technology, Faculty of Pharmacy in Hradec Kralove, Charles University, Akademika Heyrovskeho 1203, 500 05 Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
BVBarbora Vraníková
Barbora Vraníková
ANAndreas Niederquell
Andreas Niederquell
ZŠZdenka Šklubalová
Zdenka Šklubalová
MKMartin Kuentz
Martin Kuentz

1 March 2020 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
BVBarbora Vraníková
Barbora Vraníková
ANAndreas Niederquell
Andreas Niederquell
FDFelix Ditzinger
Felix Ditzinger
ZŠZdenka Šklubalová
Zdenka Šklubalová
MKMartin Kuentz
Martin Kuentz

2 August 2017 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
LZLukáš Zahálka
Lukáš Zahálka
SKSylva Klovrzová
Sylva Klovrzová
LMLudmila Matysová
Ludmila Matysová
ZŠZdenka Šklubalová
Zdenka Šklubalová
PSPetr Solich
Petr Solich
Background Oral liquid solutions of the diuretic active ingredient furosemide (FUR) marketed across Europe do not comply with recent requirements for paediatric preparation owing to their ethanol content and, moreover, in some countries only tablet or injection dosage forms of furosemide are available. Objectives To formulate extemporaneous paediatric ethanol-free solutions of FUR (2 mg/mL) with suitable solubility in the aqueous vehicle and an acceptable taste and to evaluate their stability under two different storage conditions during a 9-month study period. Methods Our work presents two developed formulations of FUR ethanol-free paediatric oral solutions 2 mg/mL for easy extemporaneous compounding in a pharmacy. FUR solubility avoiding the use of ethanol was achieved using sodium hydroxide (formulation F1) or disodium hydrogen phosphate dodecahydrate (formulation F2). The preparations were stored at 25°C±3°C or at 40°C±0.5°C and protected from light. For FUR and preservative, methylparaben (MP), a stability assay was conducted by a high-performance liquid chromatography validated method and determination of pH stability. Results The remaining FUR concentration was >90% of the initial concentration after 270 days in both formulations at both storage conditions, 25°C and 40°C. The concentration of MP decreased significantly in the formulation F2 stored at 40°C. Conclusions Both formulations were stable when stored at room temperature for up to 9 months; formulation F1 was stable even at 40°C. MP used as an antimicrobial agent fully satisfied the recommended criteria for preservative efficacy in oral preparations according to the European Pharmacopoeia 9.0 (5.1.3).

1 October 2021 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
OMOliver Macho
Oliver Macho
ĽGĽudmila Gabrišová
Ľudmila Gabrišová
JBJana Brokešová
Jana Brokešová
PSPetra Svačinová
Petra Svačinová
JMJitka Mužíková
Jitka Mužíková
ZŠZdenka Šklubalová
Zdenka Šklubalová

23 November 2017 in Journal of Pharmaceutical Innovation
Verified
Journal Article
Closed access
PDF file
HHHana Hurychová
Hana Hurychová
MKMartin Kuentz
Martin Kuentz
ZŠZdenka Šklubalová
Zdenka Šklubalová

16 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MDMartin Dominik
Martin Dominik
BVBarbora Vraníková
Barbora Vraníková
PSPetra Svačinová
Petra Svačinová
JEJan Elbl
Jan Elbl
SPSylvie Pavloková
Sylvie Pavloková
AFAleš Franc
Aleš Franc
The utilization of co-processed excipients (CPEs) represents a novel approach to the preparation of orally disintegrating tablets by direct compression. Flow, consolidation, and compression properties of four lactose-based CPEs—Cellactose® 80, CombiLac®, MicroceLac® 100, and StarLac®—were investigated using different methods, including granulometry, powder rheometry, and tablet compaction under three pressures. Due to the similar composition and the same preparation technique (spray drying), the properties of CPEs and their compacts were generally comparable. The most pronounced differences were observed in flowability, undissolved fraction after 3 min and 24 h, energy of plastic deformation (E2), ejection force, consolidation behavior, and compact friability. Cellactose® 80 exhibited the most pronounced consolidation behavior, the lowest values of ejection force, and high friability of compacts. CombiLac® showed excellent flow properties but insufficient friability, except for compacts prepared at the highest compression pressure (182 MPa). MicroceLac® 100 displayed the poorest flow properties, lower ejection forces, and the best mechanical resistance of compacts. StarLac® showed excellent flow properties, the lowest amounts of undissolved fraction, the highest ejection force values, and the worst compact mechanical resistance. The obtained results revealed that higher compression pressures need to be used or further excipients have to be added to all tested materials in order to improve the friability and tensile strength of formed tablets, except for MicroceLac® 100.